richapd
$CRDF The 30 mg arm had 5 surgical conversions which is a big deal because data shows that the mPFS from the date of conversion is 20 months in one study. Surgical conversions are usually not performed until after 3-5 months of chemotherapy bringing the expected mPFS from their initiation on trial to 23-25 months for those 5 patients. Furthermore, the 30mg arm CR's(without surgical conversion) will have a much higher mPFS because their tumor bulk was driven down more logs volume than the PR's(seen with chemo/bev alone), thus requiring much longer time for regrowth to the point of progression(>5mm size tumor). Like Bull Run4 said, it would be nice/needful/expedient... to see some data granularity reported. I can't but believe there are some suitors interested in this singular data. Also, reviewing the toxicity data is extraordinary that there was essentially no added toxicity to the chemo/bev alone. That points to the exquisite specificity targeting PLK1 and not PLK's 2-5. The lack of toxicity allows ONV to be combined with anything essentially.
26
